

# Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans

Luigi Fontana,<sup>1,2</sup> J. Christopher Eagon,<sup>1</sup> Maria E. Trujillo,<sup>3,4</sup> Philipp E. Scherer,<sup>3,4</sup> and Samuel Klein<sup>1</sup>

Although excess visceral fat is associated with noninfectious inflammation, it is not clear whether visceral fat is simply associated with or actually causes metabolic disease in humans. To evaluate the hypothesis that visceral fat promotes systemic inflammation by secreting inflammatory adipokines into the portal circulation that drains visceral fat, we determined adipokine arteriovenous concentration differences across visceral fat, by obtaining portal vein and radial artery blood samples, in 25 extremely obese subjects (mean  $\pm$  SD BMI  $54.7 \pm 12.6$  kg/m<sup>2</sup>) during gastric bypass surgery at Barnes-Jewish Hospital in St. Louis, Missouri. Mean plasma interleukin (IL)-6 concentration was  $\sim$ 50% greater in the portal vein than in the radial artery in obese subjects ( $P = 0.007$ ). Portal vein IL-6 concentration correlated directly with systemic C-reactive protein concentrations ( $r = 0.544$ ,  $P = 0.005$ ). Mean plasma leptin concentration was  $\sim$ 20% lower in the portal vein than in the radial artery in obese subjects ( $P = 0.0002$ ). Plasma tumor necrosis factor- $\alpha$ , resistin, macrophage chemoattractant protein-1, and adiponectin concentrations were similar in the portal vein and radial artery in obese subjects. These data suggest that visceral fat is an important site for IL-6 secretion and provide a potential mechanistic link between visceral fat and systemic inflammation in people with abdominal obesity. *Diabetes* 56:1010–1013, 2007

**E**xcessive visceral fat (i.e., mesenteric and omental fat) is associated with insulin resistance and diabetes (1,2). Accordingly, waist circumference, which correlates with visceral fat mass (3), has been recommended as a clinical marker to identify patients at increased risk for metabolic diseases (4), and large waist circumference is one of the criteria used to diagnose the metabolic syndrome (5). However, the mech-

anism(s) responsible for the relationship between visceral fat and metabolic abnormalities is not known, and it is not clear whether visceral fat is simply associated with or actually causes metabolic disease.

It has been hypothesized that large amounts of visceral fat cause insulin resistance because lipolysis of visceral adipose tissue triglycerides releases free fatty acids (FFA) directly into the portal vein, which are then transported to the liver (2). Increased delivery of FFA to the liver impairs insulin's ability to suppress hepatic glucose production, and increased systemic FFA concentration inhibits insulin-mediated glucose disposal in skeletal muscle (6). However, data from studies that examined FFA kinetics in human subjects suggest it is unlikely that lipolytic activity in visceral fat is a major contributor to insulin resistance (7). On average, 20% of portal vein FFA and 14% of total FFA that appear in the systemic circulation are derived from lipolysis of visceral fat in obese subjects (7,8). Therefore, fatty acids released from visceral fat represent only a small percentage of total FFA delivered to liver and muscle tissues.

Visceral fat could cause metabolic abnormalities by secreting inflammatory adipokines, such as interleukin (IL)-6, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), macrophage chemoattractant protein-1 (MCP-1), and resistin, which induce insulin resistance and diabetes (9,10). In contrast, visceral fat might have beneficial metabolic effects by producing adiponectin (11), which increases insulin sensitivity and decreases glucose intolerance and diabetes (12). However, the importance of adipokine production by visceral fat in the pathogenesis of the metabolic abnormalities associated with obesity has not been carefully studied.

The purpose of the present study was to evaluate the relative contribution of inflammatory adipokines (IL-6, TNF- $\alpha$ , MCP-1, resistin, and leptin) and adiponectin secretion from visceral fat in insulin-resistant subjects with abdominal obesity. Portal vein and peripheral artery plasma concentrations of adipokines were determined in insulin-resistant, extremely obese subjects who had large amounts of visceral fat. We hypothesized that the concentration of inflammatory adipokines would be greater in the portal vein than in the peripheral artery in obese subjects.

## RESEARCH DESIGN AND METHODS

Twenty-five subjects with class III upper-body obesity (6 male and 19 female, BMI  $54.7 \pm 12.6$  kg/m<sup>2</sup>, waist circumference  $150 \pm 10$  cm, age  $42 \pm 9$  years), who were scheduled to undergo open gastric bypass surgery, participated in this study. Subjects completed a comprehensive medical evaluation, which included history, physical examination, electrocardiogram, and standard blood and urine tests. All obese subjects had evidence of insulin resistance, based on either a history of type 2 diabetes or high homeostasis model assessment score (13). All women who participated in this study were premenopausal. Six obese subjects had type 2 diabetes and were treated with

From the <sup>1</sup>Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri; the <sup>2</sup>Division of Food Science, Human Nutrition, and Health, Istituto Superiore di Sanità, Rome, Italy; the <sup>3</sup>Department of Cell Biology, Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York; and the <sup>4</sup>Department of Medicine, Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York.

Address correspondence and reprint requests to Samuel Klein, MD, Washington University School of Medicine, Campus Box 8031, 660 South Euclid Ave., St. Louis, MO 63110. E-mail: sklein@im.wustl.edu.

Received for publication 27 November 2006 and accepted in revised form 14 January 2007.

Published ahead of print at <http://diabetes.diabetesjournals.org> on 2 February 2007. DOI: 10.2337/db06-1656.

CRP, C-reactive protein; IL, interleukin; FFA, free fatty acid; HMW, high molecular weight; LMW, low molecular weight; MCP-1, macrophage chemoattractant protein-1; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ .

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

TABLE 1  
Radial artery and portal vein plasma adipokine concentrations in obese subjects

Adipokine	Sample site		Difference (range)
	Radial artery	Portal vein	
IL-6 (pg/ml)	28.5 ± 27.6	42.1 ± 41.8*	13.6 ± 23.3 (−16.0 to 60.4)
TNF-α (pg/ml)	1.87 ± 0.8	1.93 ± 0.8	0.06 ± 0.2 (−0.4 to 0.6)
MCP-1 (pg/ml)	205 ± 88	190 ± 99	−14.7 ± 82.2 (−202 to 198)
Resistin (pg/ml)	18.5 ± 11	18.1 ± 11	−0.4 ± 2.6 (−8.1 to 4.2)
Leptin (ng/ml)	101 ± 51	81 ± 42†	−19 ± 21 (−80.0 to 16.0)
Total adiponectin (μg/ml)	14.3 ± 10	14.7 ± 11	0.4 ± 3.1 (−7.0 to 7.1)

Data are means ± SD. Significantly different from corresponding radial artery value, \* $P = 0.007$ ; † $P = 0.0002$ .

insulin and metformin; none were being treated with thiazolidinediones. Each subject provided written informed consent before enrolling in the study, which was approved by the Human Studies Committee of the Washington University School of Medicine in St. Louis, Missouri.

Open gastric bypass surgery and upper gastrointestinal tract surgery were performed in the morning at Barnes-Jewish Hospital after subjects had fasted overnight. During the operation, blood samples were obtained simultaneously from the radial artery and portal vein before gastric stapling or intestinal resection was initiated. Blood samples were immediately transferred to sterile glass EDTA tubes (BD Vacutainer; BD Biosciences, Oxford, U.K.), placed on ice, and centrifuged at 2,200g for 10 min at 4°C. Aliquots of plasma were then placed in sterile cryovials, snapfrozen in liquid nitrogen, and stored at −80°C until subsequent analyses were performed.

**Sample analyses.** Commercial radioimmunoassay kits were used to measure plasma total adiponectin (Linco Research, St. Louis, MO), and commercial ELISA kits were used to measure IL-6, TNF-α, resistin, MCP-1 (Quantakine High Sensitive; R&D Systems, Minneapolis, MN), and plasma C-reactive protein (CRP) (ALPCO Diagnostics, Windham, NH) concentrations. Plasma high-molecular weight (HMW) and low-molecular weight (LMW) adiponectin were determined by velocity sedimentation and quantitative Western blot analysis (14). Plasma insulin and leptin concentrations were measured by radioimmunoassay (Linco Research, St. Louis, MO).

**Statistical analyses.** The statistical significance of differences between blood sampling sites was evaluated by using Student's paired  $t$  test for data that was normally distributed with approximately equal SD values. The statistical significance of differences between groups that were not normally distributed or that had unequal SDs was evaluated by using the Wilcoxon two-samples test for variables. Pearson correlation was used to assess associations between continuous variables. Correlation data were log transformed when the data were not normally distributed. A  $P$  value <0.05 was considered statistically significant. All data were analyzed by using SPSS for Windows software, version 12.0 (SPSS, Chicago, IL). All values are expressed as means ± SD.

## RESULTS

Portal vein and peripheral artery blood samples were obtained simultaneously from 25 subjects with extreme obesity (BMI  $54.7 \pm 12.6$  kg/m<sup>2</sup>) and large visceral fat mass (waist circumference  $150 \pm 10$  cm) during open gastric bypass surgery. All obese subjects had evidence of insulin resistance based on the homeostasis model assessment of insulin resistance (13).

In obese subjects, mean plasma insulin concentration was more than twofold greater in the portal vein than in the peripheral artery ( $34.4 \pm 21$  and  $15.2 \pm 8$  μU/ml, respectively;  $P = 0.0004$ ). Plasma IL-6 concentration was ~50% higher in the portal vein than in the peripheral artery (Table 1). Plasma leptin concentration was ~20% lower in the portal vein than in the peripheral artery. In contrast, portal vein plasma TNF-α, MCP-1, resistin, and total adiponectin concentrations were not significantly different from their peripheral artery concentrations. The percentage of adiponectin present as the HMW form in the portal vein and radial artery were evaluated in a subset of 10 obese subjects; no significant difference in percentage of HMW adiponectin was found between the portal vein ( $33.1 \pm 11\%$ ) and artery ( $28.6 \pm 17\%$ ). Portal vein IL-6

concentrations correlated directly with arterial CRP concentrations (Fig. 1).

## DISCUSSION

The importance of adipokines released from visceral fat in the pathogenesis of insulin resistance and systemic inflammation has not been carefully studied in human subjects because of the difficulty in gaining access to portal vein blood. The portal vein, which drains visceral fat, is the major source of blood supply to the liver and is responsible for ~80% of total liver blood flow (15). In the present study, we obtained blood samples from the portal vein and radial artery during open gastric bypass surgery in morbidly obese subjects who had a large amount of intra-abdominal fat. Plasma IL-6 concentrations were much higher in portal vein than in peripheral artery blood in obese subjects, demonstrating that visceral fat is an important source of IL-6 production in obese people. These data are consistent with previous ex vivo findings that IL-6 secretion is greater in omental than in subcutaneous adipose tissue samples (16,17). Moreover, portal vein IL-6 concentrations correlated directly with arterial CRP concentrations in obese subjects. These results provide the first evidence of a potential mechanistic link between visceral fat mass and systemic inflammation in human subjects.




FIG. 1. Relationship between portal vein IL-6 and systemic CRP concentrations in extremely obese subjects. Data are log transformed.

The direct secretion of IL-6 into the portal vein has important metabolic consequences because IL-6 stimulates hepatic acute-phase reactant production (18), impairs insulin-mediated glycogenesis (19), and stimulates hepatic gluconeogenesis (20). Increased serum IL-6 concentration is also associated with increased risk of developing type 2 diabetes and cardiovascular disease (21–23). In our obese subjects, portal vein IL-6 concentrations correlated directly with systemic CRP concentrations, suggesting that IL-6 delivery to the liver contributes to the regulation of CRP production. This observation provides a potential mechanism for the relationship between visceral fat and systemic insulin resistance and supports the possibility that visceral fat is involved in regulating the hepatic production of acute-phase reactants that activate inflammatory pathways (24). These findings are consistent with data obtained from LKK mice, showing that a localized increase in nuclear factor- $\kappa$ B and inflammation in the liver can cause peripheral insulin resistance in skeletal muscle (25). In addition, we have previously found that there is a considerable net release of IL-6 from subcutaneous abdominal fat in vivo, and this release is greater in obese than in lean subjects (26). Therefore, both visceral and subcutaneous fat depots in obese persons produce a large portion of circulating IL-6 during basal conditions.

Plasma leptin concentrations were lower in portal vein than in peripheral artery blood in our subjects. The lower portal vein leptin concentration is consistent with data obtained in vitro from isolated adipose tissue, showing that the expression of the *ob* gene, which produces leptin, and leptin secretion are lower in omental than subcutaneous fat (27,28).

In contrast with IL-6 and leptin, the plasma concentrations of other potential inflammatory adipokines, such as TNF- $\alpha$  and resistin, were similar in the portal vein and peripheral artery. These results are not surprising, based on what is known about the production and breakdown of these adipokines. Although TNF- $\alpha$  production is upregulated in visceral fat (29), it is likely that this cytokine acts locally and is not primarily released into the bloodstream. In fact, we have previously found that there is no net release of TNF- $\alpha$  from subcutaneous abdominal fat in vivo (26). Resistin is exclusively produced by adipocytes in mice (30), but resistin expression in humans is more prominent in monocytes and macrophages (31). Adiponectin circulates in plasma primarily as a LMW hexamer and as a larger, multimeric HMW complex (32). The HMW protein, but not the LMW form, has direct beneficial metabolic effects in the liver by increasing hepatic insulin sensitivity and decreasing hepatic glucose production (33–34). In addition, treatment with recombinant adiponectin has been shown to decrease hepatomegaly, steatosis, hepatic inflammation, and serum transaminase concentrations in a mouse model of nonalcoholic steatohepatitis (35). Therefore, preferential production of HMW adiponectin by visceral fat could have direct beneficial metabolic effects on the liver that might not be identified by only measuring total adiponectin concentrations. However, we found no differences between portal and systemic total, HMW, or LMW adiponectin concentrations. These findings suggest that visceral fat is not a major site for adiponectin production.

Fasting plasma insulin concentration was more than twofold greater in the portal vein than in the peripheral artery blood in the obese subjects, consistent with data reported previously (36). This observation underscores

the important strategic anatomical location of both the pancreas and visceral fat as endocrine organs that regulate hepatic glucose and lipid metabolism. Both tissues are drained by the portal circulation, which provides an efficient system for delivering protein hormones (e.g., insulin) and inflammatory cytokines (e.g., IL-6) directly to the liver, where they can modulate endogenous glucose production and the production of acute-phase inflammatory reactants.

Our study has several important limitations. First, it was conducted in subjects during postabsorptive conditions, which might not reflect adipose tissue adipokine secretion into the systemic or portal circulations during postprandial conditions. Second, blood samples were obtained during surgery, which could have affected plasma adipokine concentrations. General anesthesia can decrease portal blood flow (37), which could increase portal vein adipokine concentrations. However, a decrease in blood flow should have simultaneously affected all adipokines secreted by visceral fat, whereas we found that portal vein IL-6 concentrations were higher and leptin concentrations lower than in radial artery blood. Third, our study subjects were limited to extremely obese subjects (BMI >40 kg/m<sup>2</sup>) who had massive amounts of intra-abdominal fat. Therefore, these results might not necessarily apply to obese people who have lower BMI values and lesser amounts of intra-abdominal fat. However, we did not find any significant correlation among BMI or waist circumference and portal vein or arterial adipokine concentrations. Fourth, the association we observed between portal vein IL-6 and systemic CRP concentrations does not prove a causal relationship. Additional and very complex studies, involving portal vein infusion of IL-6 inhibitors and recombinant portal vein IL-6, will be needed to prove that portal vein IL-6 is a major regulator of CRP production.

The results of the present studies support the notion that visceral fat is an important endocrine organ that is involved in the complex interrelationship between obesity and systemic inflammation. Our findings suggest that increased IL-6 secretion from visceral fat into the portal circulation is involved in the pathogenesis of systemic metabolic abnormalities associated with abdominal obesity.

#### ACKNOWLEDGMENTS

This study was supported by National Institutes of Health Grant DK-37948, General Clinical Research Center Grant RR-00036, Diabetes Research and Training Center Grant DK-20579, and Clinical Nutrition Research Unit Grant DK56341. The funding agency had no role in the analysis or interpretation of the data or in the decision to submit the report for publication.

The study design was developed by S.K. and L.F.; data collection was performed and supervised by L.F., J.C.E., M.E.T., P.E.S., and S.K.; data analyses and interpretation were performed by L.F., M.E.T., P.E.S., and S.K.; writing was performed by L.F. and S.K. L.F. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Jennifer McCrea and Jennifer Shew for technical assistance.

#### REFERENCES

- Montague CT, O'Rahilly S: The perils of portliness: causes and consequences of visceral adiposity. *Diabetes* 49:883–888, 2000
- Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. *Arteriosclerosis* 10:497–511, 1990



3. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ: Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol* 73:460–468, 1994
4. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB: Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. *Am J Clin Nutr* 76:743–749, 2002
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, National Heart, Lung, and Blood Institute, American Heart Association: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 109:433–438, 2004
6. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. *Diabetes* 46:3–10, 1997
7. Nielsen S, Guo ZK, Johnson CM, Hensrud DD, Jensen MD: Splanchnic lipolysis in human obesity. *J Clin Invest* 113:1582–1588, 2004
8. Klein S: The case of visceral fat: argument for the defense. *J Clin Invest* 113:1530–1532, 2004
9. Lafontan M: Fat cells: afferent and efferent messages define new approaches to treat obesity. *Annu Rev Pharmacol Toxicol* 45:119–146, 2004
10. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 112:1821–1830, 2003
11. Park KG, Park KS, Kim MJ, Kim HS, Suh YS, Ahn JD, Park KK, Chang YC, Lee IK: Relationship between serum adiponectin and leptin concentrations and body fat distribution. *Diabetes Res Clin Pract* 63:135–142, 2004
12. Trujillo ME, Scherer PE: Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. *J Intern Med* 257:167–175, 2005
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412–419, 1985
14. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE: Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin: implications for metabolic regulation and bioactivity. *J Biol Chem* 278:9073–9085, 2003
15. Schenk WG Jr, McDonald JC, McDonald K, Drapanas T: Direct measurement of hepatic blood flow in surgical patients: with related observations on hepatic flow dynamics in experimental animals. *Ann Surg* 156:463–471, 1962
16. Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. *J Clin Endocrinol Metab* 83:847–850, 1998
17. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. *Endocrinology* 145:2273–2282, 2004
18. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. *Biochem J* 265:621–636, 1990
19. Senn JJ, Klover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. *Diabetes* 51:3391–3399, 2002
20. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP: Dose dependent effects of recombinant human interleukin-6 on glucose regulation. *J Clin Endocrinol Metab* 82:4167–4170, 1997
21. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. *Diabetologia* 40:1286–1292, 1997
22. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 286:327–334, 2001
23. Plutzky J: Inflammatory pathways in atherosclerosis and acute coronary syndromes. *Am J Cardiol* 88:10K–15K, 2001
24. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES: Activation of inflammation and coagulation after infusion of C-reactive protein in humans. *Circ Res* 96:714–716, 2005
25. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat Med* 11:183–190, 2005
26. Mohamed-Ali V, Goodrick SJ, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6 but not tumor necrosis factor-alpha in vivo. *J Clin Endocrinol Metab* 82:4196–4200, 1997
27. Ramis JM, Bibiloni B, Moreira J, Garcia-Sanz JM, Salinas R, Proenza AM, Llado I: Tissue leptin and plasma insulin are associated with lipoprotein lipase activity in severely obese patients. *J Nutr Biochem* 16:279–285, 2005
28. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P: Leptin secretion from subcutaneous and visceral adipose tissue in women. *Diabetes* 47:913–917, 1998
29. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. *J Clin Invest* 95:2409–2415, 1995
30. Stepan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. *Nature* 409:307–312, 2001
31. Patel L, Buckels AC, Kinghorn LJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. *Biochem Biophys Res Commun* 300:472–476, 2003
32. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. *J Biol Chem* 279:12152–12162, 2004
33. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A, Lemieux I, Despres JP: Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. *J Clin Endocrinol Metab* 90:1434–1439, 2005
34. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat Med* 7:947–953, 2001
35. Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. *J Clin Invest* 112:91–100, 2003
36. Horwitz DL, Starr JJ, Mako ME, Blackard WG, Rubenstein AH: Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. *J Clin Invest* 55:1278–1283, 1975
37. Gelman S: General anesthesia and hepatic circulation. *Can J Physiol Pharmacol* 65:1762–1779, 1987